English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

Kinex Licenses China Rights for Cancer Molecule to Hanmi Pharma

Apr. 20, 2011

Kinex Pharmaceuticals, a New York State based, privately held pharma company, has out-licensed China rights for its lead molecule, KX01, to Hanmi Pharmaceutical Co. of South Korea. KX01 has completed a Phase I trial for end-stage cancer in the US, where it showed a clinical response in 25% of the patients. Hanmi has rights to KX01 in China and other selected Asian countries for all oncology indications. Financial terms were not disclosed.